



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

SEP - 7 2004

In re Application of:

Daniel E. Afar, et al

Serial No. 09/389,000

Filed: 8/31/1999

For: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED
IN CANCER

NOTICE OF WITHDRAWAL
FROM ISSUE
UNDER 37 CFR 1.313

The purpose of this communication is to inform you that the above-identified application is being withdrawn from issue pursuant to 37 CFR 1.313.

The application is being withdrawn to permit reopening of prosecution. The examiner therefor will communicate the reasons to you.

The issue fee is refundable upon written request. If, however, the application is again found allowable, the issue fee can be applied toward payment of the issue fee in the amount identified on the new Notice of Allowance and Issue Fee Due upon written request. This request and any balance due must be received on or before the due date noted in the new Notice of Allowance in order to prevent abandonment of the application.

Telephone inquiries should be directed to Jeffrey Siew
(571) 272-0787.

Jasemine C. Chambers

Jasemine C. Chambers, Director
Technology Center 1600

AGENSYS C/O MORRISON & FOERSTER, LLP
3811 VALLEY CENTRE DRIVE
SUITE 500
SAN DIEGO, CA 92130